12th PROGRAM
Dec. 9-12, 2018

“Health Care Technological Innovation– From Idea to Commercialization” The Twelves Course

An Executive Program for Biotechnology, Medical Device and Health It Entrepreneurs and Managers Offered by:
The Coller School of Business, Tel Aviv University
Lahav Executive Education
And In collaboration with

Israel Advanced Technology Industries Organization (IATI)

Dec. 9-12, 2018 – Sunday through Wednesday, Tel Aviv, Israel

Program Directors:

Program Founder For the IATI

Dr. Benny Zeevi

Managing General Partner, Tel Aviv Venture Partners

Vice President

Robert Goldberg, Ph.D.

The Center for Medicine in the Public Interest

Program Director

Michael Berman

Medical Device Investor / Entrepreneur

Past President of the Cardiology Business at Boston Scientific

[/vc_row]

Sunday, December 9th, 2018

Day’s Theme: The Creative Process and Technology Assessment


 

  • 8:30 AM – 9:00 AM | Registration/Administrative & Continental Breakfast

 


 

  • 9:00 – 9:30 AM | Session 1:  Welcome and Opening Remarks:

Prof. Moshe Zviran, Dean, Coller School of Management, Tel Aviv University

 

Course Directors:

Introduction to Program Structure and review of required assignments –

Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners

 


 

  • 9:30 – 10:15 AM | Session 2: Keynote Lecture: TBD

 


 

  • 10:15 AM – 11:15 AM | Session 3: The Persuasive Pitch, Part 1: Introduction of course participants

Barry Katz, Founder and CEO, Barry Katz Communicating Success

In order to give participants a chance to learn more about their colleagues in the course, and as the first part of our special focus on presentations, we are asking each participant to prepare to deliver a 3 minute presentation, using 4-5 power point slides, to introduce yourself and your company to the group

 


 

  • 11:15 – 11:45 AM | Coffe Break

 


 

  • 11:45 – 1:30 PM | Session 4: The Persuasive Pitch, Part 2: Introduction of course participants

 


 

  • 1:30 – 2:30 PM | Networking Lunch

 


 

  • 2:30 PM – 3:30 PM | Session 4: Project, Product or Company?: Assessment and Qualification of Technologies as a Basis for a Startup

Healthcare (Medicine) has to actively adopt Innovation in its teaching and culture, rather than letting it occur passively. Innovation is needed to overcome the many unmet needs that exist in Healthcare (Medicine) today
The successful translation of discoveries from the lab to the market is the greatest challenge facing an entrepreneur. Many companies are formed on technologies emanating from university laboratories and spinouts from major corporations as well as new ideas originating by life science companies ventures. One has to define what is the objective vs. what is possible in the healthcare market. Many healthcare innovations fall because they neither integrate with existing clinical practice nor are successful in creating new ones. This session will provide tools and a contextual framework as to how technologies can be assessed by founders, corporations and VCs so that they can orient and characterize their business for capitalization and partnering.

Moderator: Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners
Evan Norton, Divisional Vice President, Abbott Ventures


 

  • 3:30 – 4:15 PM | Session 5: Keynote Lecture- The New “Kids” on the Block: Microbiome

Mike Berman, medical device investor/entrepreneur, past President of the Cardiology business of Boston Scientific

 


 

  • 4:15 PM – 4:35 | Coffee Break

 


 

  • 4:35 – 6:00 PM | Session 6: Market Analysis and Competitive Analysis – Essentials of Marketing in life Sciences Companies

This session will focus on Market analysis, Clinical state of the art and product positioning: assessment of different applications for the same product (choosing the right application from commercial point of view), Determination of subgroup of patients most appropriate for the product, Competitive analysis, Importance of opinion leaders, patients groups, patients organization and Selling strategy: To build mutually satisfying long-term relationships with key customers in order to acquire and retain their business.
Competitive analysis — product differentiation linked to improvements in efficiency and effectiveness – can help potential customers’ better grasp the implication of economic value for their own businesses. Economic value to the customer analyses are calculated as cost savings, improvements in long-term client retention, decreased speed in client acquisition, increased average revenue/customer, and revenue associated with the opportunity/ability to establish entry barriers. Often times, making these explicit links from the market and competitive data can lead to powerful insights as to the value of the offering to the customer, and help make a transformative difference in outcome.

Moderator: Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners
Evan Norton, Divisional Vice President, Abbott Ventures
Bob Gold, Clinical Behavioral Technologist and CEO GoMo Health

 


  • 6:00 PM  | End of the day

* Changes in curriculum may occur

Monday, December 10th, 2018

Day’s Theme: Strategy and Execution


 

  • 8:30 – 9:00 AM | Continental Breakfast

 


 

  • 9:00 AM – 10:00 AM | Session 7: Keynote lecture – “The Collision of Med Tech with Info Tech”…accessing, programing and receiving health from the palm

Peter J. Fitzgerald, MD, PhD, FACC, Professor Emeritus, Medicine & Engineering, Director, Center for Cardiovascular Technology, Stanford University, Co-founder, Managing Partner, Triventures

 


 

  • 10:00 AM – 11:00 AM | Session 8: Keynote Lecture – What it takes to have a successful medical device venture and how to lead to success

Andrew M. Weiss, President & CEO ReCor Medical

 


 

  • 11:00 – 11:20 AM | Coffee Break

 


 

  • 11:20 AM – 12:40 PM | Session 9: Capitalization of a life science Venture –Value inflection Points, Milestones and Capital Requirements, Alternative financing, Terms etc.

Financing a life science venture is challenging. When meeting with investors and prospective strategic partners, entrepreneurs will often hear questions that ask: Where are you in the value chain?” How does your business model reflect this?” “How do you describe your milestones and how are you managing towards them?” How do your milestones tie-in with your value inflection points?” This session will consist of a brief overview of typical value inflection points for each type of product, classical and alternative ways of financing, terms of financing rounds and more.

Moderator: Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners
Andrew M. Weiss, President & CEO ReCor Medical
Dr. Ayal Shenhav, Shenhav & Co –Term Sheet, investment agreements
Dr. Ora Dar, Israel Innovation Authority
Evan Norton, Divisional Vice President, Abbott Ventures
Allen Kamer, Managing Partner, OurCrowd Qure

 


 

  • 12:40 – 1:40 PM | Session 9- Part 2: Capitalization of a life science Venture –Value inflection Points, Milestones and Capital Requirements, Alternative financing, Terms etc.

 


 

  • 1:40 – 2:40 PM | Networking Luncheon

 


 

  • 2:40 – 3:40 PM | Session 10: Team Building, Organization Development and Board Management

Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners
Andrew M. Weiss, President & CEO ReCor Medical

 


 

  • 3:40 – 4:40 PM | Session 11: The Persuasive Pitch, Part 2: Presenting Your Idea—and Yourself—With Purpose, Clarity, and Power

On the path from ‘idea to commercialization’ you will need to communicate persuasively about your product, your company, and yourself to a wide range of audiences—investors, regulators, partners, customers, and your own team. During this session we will focus on one of the most common—and, perhaps surprisingly, often one of the more difficult—types of presentations that entrepreneurs must deliver: the short introduction.

Barry Katz, Founder and CEO, Barry Katz Communicating Success

 


 

  • 4:40 – 5:00 PM | Coffee Break

 


 

  • 5:00 – 6:00 PM | Session 12: Intellectual Capital Management

The goal of the session is to provide information and insight into the specific issues confronting investigators, entrepreneurs, investors and their patent attorneys. The session will address the formation of specific IP strategy and execution and using intellectual capital for competitive advantage. Content includes major issues confronting companies with US and filings in other jurisdictions related to biotechnology, e.g., patent ownership, non-obviousness rulings, the scope of what can be patented. A VC will also provide an investor viewpoint.

Brian Hopkins, Special Counsel, Cooley LLP

 


 

  • 6:00 – 7:20 PM | Session 13: Incorporating Reimbursement in the Company Development Strategy

Moderator: Bob Goldberg Ph.D., Vice President, The Center for Medicine in the Public Interest
Stuart Kurlander, Healthcare and Life Sciences Partner at Latham & Watkins LLP

Mike Berman, medical device investor/entrepreneur, past President of the Cardiology business of Boston Scientific

 


 

  • 7:20 – 7:30 PM | Drive to opening dinner at the “Duplex” (1 Ha’Etzel st. Herzliya Pituah, 2nd floor)

 


 

  • 7:30 PM | Opening Dinner for Faculty, Participants and life sciences executives
    At the “Duplex”

Lecture: Avi Yaron, A visionary entrepreneur, Executive Chairman and strategic adviser

A personal journey into the future of medicine,  triggered by the diagnosis of an inoperable brain tumor

 


 

* Changes in curriculum may occur

Tuesday, December 11th, 2018

Day’s Theme: Bringing the product to the market

  • 8:30 – 9:00 AM | Continental Breakfast

 


 

  • 9:00 – 10:00 AM | Session 14: Best Practices in Securing Paid Trials

Best practices in securing initial and eventually paid trials are generally well understood; we know that success also tends to follow from tactical relentless and persistence.  There also exist a number of more nuanced elements that can contribute to success in execution, which we explore here.  This session draws on interviews with decision-makers in large healthcare systems to compare/contrast the processes followed by ventures that were successful vs. not.  It also draw on primary data and case studies with new ventures, and documents the outcomes that resulted from different decisions taken in implementation and negotiation both within trials and across trials.

Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners

 


 

  • 10:00 – 11:30 AM | Session 15 Lessons learned from our experience: A panel of life science CEOs and Entrepreneurs

In this session we will have several Israeli and US CEOs in life sciences sharing their experience.
Specifically addressing issues: Building a management team, financing, collaborations, dealing with the board, working with cross-border teams and more
Moderator: Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners
Andrew M. Weiss, President & CEO ReCor Medical
Avner Halprin, CEO, Early Sense
Roni Mamluk, PhD, CEO, Ayala Pharmaceuticals
Yael Margolin, President, Gamida Cell
Bob Gold, Clinical Behavioral Technologist and CEO GoMo Health

 


 

  • 11:30 AM – 11:50 AM | Coffee Break

 


 

  • 11:50 AM – 13:40 PM | Session 16: Biotechnology and Medical device Regulatory Planning, Clinical Development and the Implications for Strategy and Financing: From Proof of Concept to Marketing Success. Designing and conducting clinical trials

This session provides an abbreviated view of the overall process and specific insight into planning for FDA regulations in light of strategy, financial needs, and the concerns of prospective partners and investors. Entrepreneurs need to understand that there is an increasing need to perform clinical studies to support medical device safety and performance claims. They also need to have a basic understanding of the activities, resources and costs associated with the design and conduct of clinical studies. The failure to incorporate an effective clinical strategy into new project planning can lead to significant project and funding delays or, worse, the failure of the project. This session will provide an overview of the increasing need for device clinical study data; key activities, resource needs and costs; and planning for the successful design and conduct of medical device clinical studies for acceptance in the United States and Europe, even when these studies are conducted outside of these regulatory jurisdictions.
Faculty:
Susan Alpert, PhD, MD, Principal, SFA Consulting LLC, Former Senior Vice President, Chief Regulatory Officer of Medtronic, Former Director, Office of Device Evaluation, CDRH at the FDA
Andrew M. Weiss, President & CEO ReCor Medical – Clinical & Pre-Clinical evidence to support a medical device company, Trial Strategy and Conducting Multi-site Clinical Trials

 


 

  • 1:40 – 2:40 PM | Networking Luncheon

 

  • 2:40 – 4:30 PM | Session 17:Biopharmaceutical and Medical Device Licensing, Partnering and Strategic Alliances

Major practical issues in formulation of partnering goals and managing different types of strategic alliances, preparation for positioning for partnering, identifying and qualifying prospective partners, making the approach, negotiation, closing the deal, with special emphasis on how to design alliances and avoid many potential problems and complications in managing these relationship.
Moderator: Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners
Bruce H. Francis, M.D. FACP, FACE, Former Medical Affairs and Drug Development Executive at J&J, Novartis and Eisai Inc
Maya Racine – Netser, Adv, COO of Voyager Analytics, Former partner and head of the High Tech Practice, Herzog, Fox & Neeman

 


 

  • 4:30 – 4:50 PM | Coffee Break

 

 


 

  • 4:50 – 5:30 PM | Session 18:“Israel entity vs. US entity-what you need to know for financial and tax implications”

John Lieberman, Perelson Weiner LLP


 

  • 5:30 – 6:15 PM | Session 19: Session 19: “We need Platform Solutions”

The rate of health care technological innovation is growing at an accelerating rate. Partly as a result, entrepreneurs are increasingly finding new and more refine opportunities for differentiation. On the one hand, this suggests more highly-specialized solutions. On the other hand, it also suggests it will likely become more difficult for entrepreneurs to communicate their solution’s role in the value chain — and consequently for decision-makers to evaluate and purchase. We can expect that decision-makers will therefore take longer, and begin to trend towards the larger corporate players offering “full packages.” While one option is for entrepreneurs to create corporate partnerships for distribution, another is for them to partner amongst themselves, and offer platform-based solutions. This discuss will focus on examples of what those options look like, how to structure them, and how they might confer competitive advantage in generating sales and going to market.

Dr. Leslie Broudo-Mitts, Head, Coller Institute of Venture and Sofaer Global MBA, Coller School of Management, Tel Aviv University


  • 6:15 PM | End of the day

 

* Changes in curriculum may occur

Wednesday, December 12th, 2018

Day’s Theme – Health Care IT\Digital Health


 

  • 8:30 – 9:00 AM | Continental Breakfast

 


 

  • 9:00 – 10:15 AM | Session 20: The Opportunities Challenges of Digital Health

Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners 

 


 

  • 10:15 AM – 11:30 AM | Session 21:  Healthcare IT and Digital Health- Part I

Healthcare IT and Digital health, with all its subsectors, is reimaging the way we consume and deliver healthcare. It enables health and wellness to be delivered through mass personalization anywhere and anytime in a predictive, personalized, participatory and preventive ways. For vast adoption, digital health technologies have to prove value, meaning a better outcome in a cost effective way.
Israel as the start-up nation and leading innovation hub in information, communication, mobile and cyber technologies, with almost 30 years of expertize in implementing health IT, EHR, health information exchange, business analytics in its healthcare system, with more than 400 active start-ups and companies in a variety of digital health related fields, can be a leading global innovation hub for digital health. Digital health technologies are facilitating fundamental shifts in healthcare; cultural and behavioral changes from all healthcare stakeholders, enhancing outcomes and quality of care and eventually will band the cost curve.
The potential applications of HCIT technologies and digital health, it’s role in global health, new business models, the use of social media by pharma and medical device companies as well as by healthcare providers and insurance companies and regulatory issues will be discussed.

 

Moderator: Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners

Tamara Mansfeld, Global Innovation Lead, Pfizer Corporate Strategy & Innovation- Pharma perspectives on Digital Health

Anat Naschitz, Managing Director, Orbimed Israel – Patients matter!

 


 

  • 11:30 AM – 11:50 AM | Coffee Break

 


 

  • 11:50 AM – 1:30 PM | Session 21 (Continue): Healthcare IT and Health Tech – Part 2

Susan Alpert, PhD, MD, Former Senior Vice President, Chief Regulatory Officer of Medtronic, Former Vice President of Regulatory Sciences for C.R. Bard, Inc., previously worked at FDA – Are Digital and Mobile Health Tools Medical Devices? Who’s Opinion Counts?

Hadas Bitran, Head of the Health Group in the Microsoft Israel R&D Center – Microsoft in Healthcare

Michal Rosen-Zvi, PhD, Director, Health Informatics IBM Research – Big Data and AI

Yael Glassman, CEO, Nutrino Health – Business models in digital health


 

  • 1:30 – 2:30 PM | Networking Luncheon

 


 

  • 2:30 – 4:30 PM | Session 21: Healthcare IT and Health Tech – Part 3

Adam Dicker, MD, PhD, FASTRO, Enterprise Senior Vice President, Professor and Chair of Enterprise Radiation Oncology, Sidney Kimmel Cancer Center, Sidney Kimmel Medical College, Thomas Jefferson University- How to develop collaboration with health care systems and approaches for clinical validation in digital health

Adam Snukal, Shareholder, Greenberg Traurig – Privacy Issues?

Allen Kamer, Managing Partner, OurCrowd Qure – “Standing-Out in a Crowded Market: How A Start-Up Can Get A Shot With A U.S. Healthcare Provider?”

 


 

  •  4:30 – 6:00 PM | Session 22: The Persuasive Pitch, Part 3: Presentations Workshop

 

Moderator: Benny Zeevi, M.D. Managing General Partner, Tel Aviv Venture Partners

Mike Berman, medical device investor/entrepreneur, past President of the Cardiology business of Boston Scientific

Bob Goldberg Ph.D., Vice President CMPI

 

 


 

  •  6:00 – 6:30 PM | Program Adjourment
    Session 23: Teams gather for “Take-aways Exercise”

Each participant will receive at registration a work-sheet to record for each session one major lesson or “take-away.”

 


 

* Changes in curriculum may occur

PLEASE SUBMIT YOUR REQUEST FOR ADDITIONAL INFORMATION ABOUT THE UPCOMING PROGRAM: